euro adhoc: quarterly or semiannual financial statement / curasan: First quarterly break-even result (E)

Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement.


Kleinostheim, 25 April 2008 - curasan AG (ISIN: DE 000 549 453 8) has succeeded in increasing its revenues of Q1/2008 by 13% compared to Q1/2007 from 2.6 million Euro to 2.9 million Euro. Due to its concurrent cost reduction the company achieved a break-even in the quarterly revenue result for the first time.

The full Q1/2008 report will be published on May 13, 2008.

About curasan AG:
curasan AG (ISIN: DE 000 549 453 8), an exchange-listed company, is a leading innovator within the growth market of bone and tissue regeneration. The company has developed a comprehensive product range centred around its synthetic bone regeneration material Cerasorb®, for use in soft and hard tissue. With the REVOIS® implant system, the company´s sales is focusing more prominently on the growth market of dental surgery/implantology. The majority of new products emerging from the substantial development pipeline are to be offered under licence within other medical fields. Please visit curasan´s corporate website at

Further inquiry note:
Dr. Erwin Amashaufer, curasan AG, Tel. +49 6027/46 86-465, email:

end of announcement euro adhoc

emitter: curasan AG
Lindigstrasse 4
D-63801 Kleinostheim
phone: +49(0)6027 4686-0
FAX: +49(0)6027 4686-686
sector: Biotechnology
ISIN: DE0005494538
indexes: CDAX, Classic All Share, Prime All Share
stockmarkets: regulated dealing/prime standard: Börse Frankfurt, free trade:
Börse Berlin, Börse Hamburg, Börse Stuttgart, Börse Düsseldorf, Börse Hannover, Börse München
language: English